SCHEMBL4642976

SCHEMBL4642976

CCn1c(=O)n(-c2nccc(-c3ccc(OC)c(OC)c3)n2)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.42
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HSD17B10 Q99714 4/20 0.41
HPGD P15428 3/20 0.41
MAPK1 P28482 3/20 0.41
TP53 P04637 2/20 0.41
TSHR P16473 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
GAA P10253 1/20 0.41
MAP3K11 Q16584 1/20 0.40
PARP1 P09874 1/20 0.40
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4648097 0.89 PDE4A (0.49) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL4642625 0.82 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4642908 0.82 KMO (0.43) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4644221 0.81 KDM4E (0.46) FAAHKDM4EALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4642768 0.78 MAP3K11 (0.50) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4642920 0.75 PDE4D (0.50) FAAHPDE4APDE4BPDE4CPDE4D
SCHEMBL4642937 0.73 PDE4D (0.50) PDE4APDE4BPDE4CPDE4DKMO
SCHEMBL4645805 0.70 PDE4D (0.45) PDE4APDE4BPDE4CPDE4DKMO
SCHEMBL4645167 0.69 PDE4D (0.44) MAP3K11PARP1PDE4APDE4BPDE4C
SCHEMBL4646063 0.69 PDE4D (0.48) PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207659-A1 INHIBITORS OF PHOSPHODIESTERASE TYPE 4 RANBAXY LABORATORIES LIMITED (IN) 2008-08-28 US claimed
EP-1958947-A1 Inhibitors of phosphodiesterase type 4 Ranbaxy Laboratories Limited (IN) 2008-08-20 EP claimed
US-20080207659-A1 INHIBITORS OF PHOSPHODIESTERASE TYPE 4 RANBAXY LABORATORIES LIMITED (IN) 2008-08-28 US disclosed
EP-1958947-A1 Inhibitors of phosphodiesterase type 4 Ranbaxy Laboratories Limited (IN) 2008-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207659-A1 INHIBITORS OF PHOSPHODIESTERASE TYPE 4 PDE4A, PDE4B, PDE4C FAAH 884/4885KDM4E 1637/4885ALDH1A1 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.